The latest price target for Immuneering (NASDAQ:IMRX) was reported by Chardan Capital on November 20, 2024. The analyst firm set a price target for $13.00 expecting IMRX to rise to within 12 months (a possible 566.67% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Immuneering (NASDAQ:IMRX) was provided by Chardan Capital, and Immuneering maintained their buy rating.

The last upgrade for Immuneering Corp happened on April 19, 2023 when Morgan Stanley raised their price target to $14. Morgan Stanley previously had an underweight for Immuneering Corp.

The last downgrade for Immuneering Corp happened on March 15, 2024 when Jefferies changed their price target from $16 to $3 for Immuneering Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immuneering, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immuneering was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest Immuneering (IMRX) rating was a maintained with a price target of $13.00 to $13.00. The current price Immuneering (IMRX) is trading at is $1.95, which is out of the analyst’s predicted range.